Biotech | November 15, 2025
Merck to acquire Cidara Therapeutics for $9.2 billion
Diversifying its portfolio to include late-phase antiviral agent
Diversifying its portfolio to include late-phase antiviral agent
Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer
The observations are procedural in nature and will be responded to within the stipulated time
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
Subscribe To Our Newsletter & Stay Updated
